These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1950529)

  • 1. Delayed onset of ototoxic effects of gentamicin in treatment of Menière's disease. Rationale for extremely low dose therapy.
    Magnusson M; Padoan S
    Acta Otolaryngol; 1991; 111(4):671-6. PubMed ID: 1950529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delayed onset of ototoxic effects of gentamicin in patients with Meniére's disease.
    Magnusson M; Padoan S; Karlberg M; Johansson R
    Acta Otolaryngol Suppl; 1991; 485():120-2. PubMed ID: 1843163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratympanic gentamicin for control of vertigo in Meniere's disease: vestibular signs that specify completion of therapy.
    Minor LB
    Am J Otol; 1999 Mar; 20(2):209-19. PubMed ID: 10100525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed onset of ototoxic effects of gentamicin in treatment of Menière's disease.
    Magnusson M; Padoan S; Karlberg M; Johansson R
    Acta Otolaryngol Suppl; 1991; 481():610-2. PubMed ID: 1927483
    [No Abstract]   [Full Text] [Related]  

  • 5. [The intratympanic treatment of Menière's disease with ototoxic antibiotics. A follow-up study of 55 cases (author's transl)].
    Lange G
    Laryngol Rhinol Otol (Stuttg); 1977 May; 56(5):409-14. PubMed ID: 141554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irritative spontaneous nystagmus following intratympanic gentamicin for Menière's disease.
    Parnes LS; Riddell D
    Laryngoscope; 1993 Jul; 103(7):745-9. PubMed ID: 8341099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratympanic therapy for Ménière's disease. High-concentration gentamicin with round-window protection.
    Quaranta A; Aloisi A; De Benedittis G; Scaringi A
    Ann N Y Acad Sci; 1999 Nov; 884():410-24. PubMed ID: 10842610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term vertigo control in patients after intratympanic gentamicin instillation for Ménière's disease.
    Bodmer D; Morong S; Stewart C; Alexander A; Chen JM; Nedzelski JM
    Otol Neurotol; 2007 Dec; 28(8):1140-4. PubMed ID: 18084826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière's disease.
    Wu IC; Minor LB
    Laryngoscope; 2003 May; 113(5):815-20. PubMed ID: 12792316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Ménière's disease by intratympanic gentamicin application.
    Assimakopoulos D; Patrikakos G
    J Laryngol Otol; 2003 Jan; 117(1):10-6. PubMed ID: 12590850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intratympanic interval therapy of Menière disease with gentamicin with preserving cochlear function].
    Lange G; Mann W; Maurer J
    HNO; 2003 Nov; 51(11):898-902. PubMed ID: 14605708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of increased gentamicin concentration for intratympanic injection therapy in Ménière's disease.
    Abou-Halawa AS; Poe DS
    Otol Neurotol; 2002 Jul; 23(4):494-502; discussion 502-3. PubMed ID: 12170152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratympanic gentamicin for Ménière's disease or syndrome.
    Pullens B; van Benthem PP
    Cochrane Database Syst Rev; 2011 Mar; (3):CD008234. PubMed ID: 21412917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratympanic gentamicin for intractable Meniere's disease.
    Perez N; Martín E; García-Tapia R
    Laryngoscope; 2003 Mar; 113(3):456-64. PubMed ID: 12616197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intratympanic gentamicin for treatment of Ménière's disease on lower frequency hearing.
    Sam G; Chung DW; van der Hoeven R; Verweij S; Becker M
    Int J Clin Pharm; 2016 Aug; 38(4):780-3. PubMed ID: 27073077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intentional ablation of vestibular function using commercially available topical gentamicin-betamethasone eardrops in patients with Meniere's disease: further evidence for topical eardrop ototoxicity.
    Kaplan DM; Hehar SS; Bance ML; Rutka JA
    Laryngoscope; 2002 Apr; 112(4):689-95. PubMed ID: 12150525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distortion product otoacoustic emissions after intratympanic gentamicin therapy for unilateral Ménière's disease.
    Perez N; Boleas MS; Martin E
    Audiol Neurootol; 2005; 10(2):69-78. PubMed ID: 15650298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratympanic gentamicin in monolateral Meniere's disease: our experience.
    Bertino G; Durso D; Manfrin M; Casati L; Mira E
    Eur Arch Otorhinolaryngol; 2006 Mar; 263(3):271-5. PubMed ID: 16021460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inner ear effects of topical gentamicin treatment in patients with Menière's disease.
    Bagger-Sjöbäck D; Bergenius J; Lundberg AM
    Am J Otol; 1990 Nov; 11(6):406-10. PubMed ID: 2285060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary results of a new delivery system for gentamicin to the inner ear in patients with Meniere's disease.
    Thomsen J; Charabi S; Tos M
    Eur Arch Otorhinolaryngol; 2000; 257(7):362-5. PubMed ID: 11052245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.